Poxel S.A. (POXEL.PA)
EUR 0.13
(-0.94%)
EUR 0.13
(-0.94%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 44.55 Million EUR | 46.67% |
| 2022 | 30.38 Million EUR | 964.88% |
| 2021 | 2.85 Million EUR | 117.21% |
| 2020 | -16.58 Million EUR | 43.89% |
| 2019 | -29.55 Million EUR | 43.72% |
| 2018 | -52.5 Million EUR | 1.7% |
| 2017 | -53.41 Million EUR | -19.5% |
| 2016 | -44.69 Million EUR | -13.83% |
| 2015 | -39.26 Million EUR | -566.23% |
| 2014 | -5.89 Million EUR | -136.63% |
| 2013 | 16.08 Million EUR | 1149.22% |
| 2012 | -1.53 Million EUR | 76.34% |
| 2011 | -6.48 Million EUR | 31.59% |
| 2010 | -9.47 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 39.23 Million EUR | 0.0% |
| 2023 FY | -2.34 Million EUR | -107.71% |
| 2023 Q4 | 44.55 Million EUR | 0.0% |
| 2022 Q2 | 17.85 Million EUR | 0.0% |
| 2022 Q4 | 30.38 Million EUR | 0.0% |
| 2022 FY | 30.38 Million EUR | 964.88% |
| 2021 FY | 2.85 Million EUR | 117.21% |
| 2021 Q4 | 2.85 Million EUR | 0.0% |
| 2021 Q2 | 111 Thousand EUR | 0.0% |
| 2020 Q4 | -16.58 Million EUR | 0.0% |
| 2020 FY | -16.58 Million EUR | 43.89% |
| 2020 Q2 | -28.38 Million EUR | 0.0% |
| 2019 Q2 | -39.89 Million EUR | 0.0% |
| 2019 Q4 | -29.55 Million EUR | 0.0% |
| 2019 FY | -29.55 Million EUR | 43.72% |
| 2018 Q2 | -93.71 Million EUR | 0.0% |
| 2018 FY | -52.5 Million EUR | 1.7% |
| 2018 Q4 | -52.5 Million EUR | 0.0% |
| 2017 Q2 | -34.06 Million EUR | 0.0% |
| 2017 FY | -53.41 Million EUR | -19.5% |
| 2017 Q4 | -53.41 Million EUR | 0.0% |
| 2016 Q2 | -30 Million EUR | 0.0% |
| 2016 FY | -44.69 Million EUR | -13.83% |
| 2016 Q4 | -44.69 Million EUR | 0.0% |
| 2015 FY | -39.26 Million EUR | -566.23% |
| 2015 Q2 | -25.33 Million EUR | 0.0% |
| 2015 Q4 | -39.26 Million EUR | 0.0% |
| 2014 Q2 | 17.62 Million EUR | 0.0% |
| 2014 Q4 | -5.89 Million EUR | 0.0% |
| 2014 FY | -5.89 Million EUR | -136.63% |
| 2013 Q4 | 16.08 Million EUR | 0.0% |
| 2013 FY | 16.08 Million EUR | 1149.22% |
| 2012 FY | -1.53 Million EUR | 76.34% |
| 2011 FY | -6.48 Million EUR | 31.59% |
| 2010 FY | -9.47 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 6340.756% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 122.679% |
| Adocia SA | 127 Thousand EUR | -34985.827% |
| Aelis Farma SA | -16.19 Million EUR | 375.191% |
| Biophytis S.A. | 2.7 Million EUR | -1548.502% |
| Advicenne S.A. | 12.17 Million EUR | -265.988% |
| genOway Société anonyme | 2.97 Million EUR | -1398.805% |
| IntegraGen SA | -709.74 Thousand EUR | 6378.135% |
| Medesis Pharma S.A. | 1.15 Million EUR | -3747.23% |
| Neovacs S.A. | -237.08 Thousand EUR | 18894.367% |
| NFL Biosciences SA | -2.27 Million EUR | 2057.889% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -922.814% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 5465.012% |
| Sensorion SA | 1.37 Million EUR | -3133.079% |
| Theranexus Société Anonyme | 2.44 Million EUR | -1723.084% |
| TME Pharma N.V. | -1.07 Million EUR | 4229.657% |
| Valbiotis SA | -18.13 Million EUR | 345.653% |
| TheraVet SA | 12.78 Thousand EUR | -348425.616% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -1943.991% |
| argenx SE | -1.83 Billion EUR | 102.426% |
| BioSenic S.A. | 28.04 Million EUR | -58.89% |
| Celyad Oncology SA | -6.1 Million EUR | 830.236% |
| DBV Technologies S.A. | -114.95 Million USD | 138.762% |
| Galapagos NV | -157.2 Million EUR | 128.344% |
| Genfit S.A. | -7.61 Million EUR | 685.455% |
| GeNeuro SA | 5.91 Million EUR | -653.908% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 277.441% |
| Innate Pharma S.A. | -30.71 Million EUR | 245.087% |
| Inventiva S.A. | 10.48 Million EUR | -324.816% |
| MaaT Pharma SA | -10.2 Million EUR | 536.639% |
| MedinCell S.A. | 39.5 Million EUR | -12.805% |
| Nanobiotix S.A. | -24.71 Million EUR | 280.269% |
| Onward Medical N.V. | -12.89 Million EUR | 445.579% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -3015.286% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | -64.249% |
| Oxurion NV | 10.71 Million EUR | -316.05% |
| Pharming Group N.V. | 99.4 Million EUR | 55.173% |
| GenSight Biologics S.A. | 16.29 Million EUR | -173.469% |
| Transgene SA | -14.4 Million EUR | 409.244% |
| Financière de Tubize SA | 78.62 Million EUR | 43.327% |
| UCB SA | 2.17 Billion EUR | 97.953% |
| Valneva SE | 82.73 Million EUR | 46.143% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 340.547% |